Condition
Acral Lentiginous Malignant Melanoma
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
4 of 4 completed with results
Key Signals
4 with results80% success
Data Visualizations
Phase Distribution
5Total
P 2 (5)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00243061Phase 2CompletedPrimary
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
NCT01395121Phase 2Completed
A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
NCT00577382Phase 2Completed
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
NCT01120275Phase 2TerminatedPrimary
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
NCT00470470Phase 2CompletedPrimary
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Showing all 5 trials